Amgen (AMGN) Shares Surge 4% After Breakthrough Sjögren’s Disease Trial Success

Quick Overview

• Shares of Amgen climbed approximately 4% during premarket hours Tuesday following encouraging Phase 3 clinical trial data for dazodalibep in treating Sjögren’s disease
• The OASIZ 301 clinical study achieved its primary endpoint, demonstrating statistically significant enhancement in systemic disease activity by Week 48
• Patient benefits emerged as soon as Week 4 and persisted throughout the entire 48-week trial duration
• Sjögren’s disease currently has no FDA-sanctioned therapies, positioning dazodalibep as a potentially groundbreaking first-in-class treatment option
• The biotech giant intends to share comprehensive trial data at a forthcoming medical conference; a companion Phase 3 study is projected to conclude in the fourth quarter of 2026

Amgen (AMGN) shares climbed approximately 4% during premarket trading Tuesday, reaching $406.02 shortly after market open, following the biotechnology company’s announcement of encouraging topline data from a Phase 3 clinical trial evaluating dazodalibep, its investigational therapy for Sjögren’s disease.

Amgen Inc., AMGN

The clinical trial, designated OASIZ 301, successfully achieved its primary endpoint. Participants demonstrated statistically significant enhancement in systemic disease activity by Week 48, as assessed using the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI).

This upward momentum propelled AMGN shares back above their 50-day moving average threshold.

The clinical investigation enrolled approximately 621 individuals diagnosed with moderate-to-severe systemic Sjögren’s disease. Data revealed patient improvements beginning at Week 4, with these therapeutic benefits sustained throughout the complete 48-week observation period.

Sjögren’s disease represents a systemic autoimmune disorder characterized by severe dryness, persistent fatigue, chronic pain symptoms, and potential involvement of vital organs. Presently, no FDA-sanctioned pharmaceutical interventions exist for this medical condition.

This absence of approved therapies constitutes a critical element of the investment narrative. Should dazodalibep successfully navigate regulatory scrutiny, it would represent the inaugural approved therapeutic option for Sjögren’s disease patients.

Understanding Dazodalibep’s Mechanism

Dazodalibep functions as a CD40L antagonist fusion protein. Its therapeutic mechanism involves blocking the cellular interactions among T cells, B cells, and additional immune system components that perpetuate the disease process.

Jay Bradner, Amgen’s chief of research and development operations, indicated that both the rapidity and persistence of the clinical outcomes strengthened the organization’s conviction in the compound and its comprehensive Phase 3 development program.

The predominant adverse events observed during the trial included nasopharyngitis, urinary tract infections, elevated blood pressure, and infusion-associated reactions. The majority registered as mild to moderate in severity. Patient withdrawal rates attributable to adverse effects remained minimal and comparable between the active treatment and placebo cohorts.

Market Competition Analysis

Amgen faces competition in this therapeutic arena. Novartis (NVS) is concurrently advancing ianalumab, a Sjögren’s disease candidate employing a distinct mechanism by targeting the BAFF protein pathway.

Ianalumab demonstrated 1.3- to 1-point superiority versus placebo on a 42-point symptom assessment scale throughout its clinical evaluation. Leerink Partners analyst David Risinger projects approval within the approaching months.

Risinger maintains a market perform rating on AMGN shares.

Amgen has committed to unveiling complete OASIZ 301 data at an imminent medical conference. The comprehensive data presentation will provide investors enhanced clarity regarding dazodalibep’s comparative positioning against ianalumab.

A supplementary Phase 3 investigation, OASIZ 303, is examining dazodalibep among patients experiencing moderate-to-severe symptomatic Sjögren’s disease. This trial is anticipated to reach completion during the fourth quarter of 2026.